AstraZeneca's investigational COVID-19 prevention therapy met its primary goals in a late-stage trial, the drugmaker said on Thursday.

AstraZeneca said that a new long-acting antibody reduced immunocompromised patients’ risks of contracting symptomatic Covid-19 infections in a large Phase 3 prevention trial. Still, it’s not clear whether the new antibody will actually reach market.

AstraZeneca said on Thursday its investigational drug, sipavibart, met primary goals in preventing COVID-19 in immunocompromised patients in a late-stage trial.